147 related articles for article (PubMed ID: 24040451)
21. p63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis.
Parsons JK; Gage WR; Nelson WG; De Marzo AM
Urology; 2001 Oct; 58(4):619-24. PubMed ID: 11597556
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Pim-1 during progression of prostatic adenocarcinoma.
Cibull TL; Jones TD; Li L; Eble JN; Ann Baldridge L; Malott SR; Luo Y; Cheng L
J Clin Pathol; 2006 Mar; 59(3):285-8. PubMed ID: 16505280
[TBL] [Abstract][Full Text] [Related]
23. Cytoskeletal and cytocontractile protein composition of stromal tissue in normal, hyperplastic, and neoplastic human prostate. An immunocytochemical study with monoclonal antibodies.
Castellucci E; Prayer-Galetti T; Roelofs M; Pampinella F; Faggian L; Gardiman M; Pagano F; Sartore S
Ann N Y Acad Sci; 1996 Apr; 784():496-508. PubMed ID: 8651605
[TBL] [Abstract][Full Text] [Related]
24. Endometrioid adenocarcinoma of the prostate: a clinicopathologic and immunohistochemical study.
Lee SS
J Surg Oncol; 1994 Apr; 55(4):235-8. PubMed ID: 7512674
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors.
Prasad ML; Pellegata NS; Huang Y; Nagaraja HN; de la Chapelle A; Kloos RT
Mod Pathol; 2005 Jan; 18(1):48-57. PubMed ID: 15272279
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
27. Metachromasia in the human prostate: a histochemical difference between benign prostatic hyperplasia and prostatic carcinoma.
Arcadi JA
J Urol; 1988 Feb; 139(2):315-7. PubMed ID: 2448498
[TBL] [Abstract][Full Text] [Related]
28. Expression of cystatins, high molecular weight cytokeratin, and proliferation markers in prostatic adenocarcinoma and hyperplasia.
Mirtti T; Alanen K; Kallajoki M; Rinne A; Söderström KO
Prostate; 2003 Mar; 54(4):290-8. PubMed ID: 12539227
[TBL] [Abstract][Full Text] [Related]
29. Downregulated gelsolin expression in hyperplastic and neoplastic lesions of the prostate.
Lee HK; Driscoll D; Asch H; Asch B; Zhang PJ
Prostate; 1999 Jun; 40(1):14-9. PubMed ID: 10344719
[TBL] [Abstract][Full Text] [Related]
30. Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer.
Eastham JA; Truong LD; Rogers E; Kattan M; Flanders KC; Scardino PT; Thompson TC
Lab Invest; 1995 Nov; 73(5):628-35. PubMed ID: 7474936
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical staining of ras p21: staining in benign and malignant prostate tissue.
Bushman EC; Nayak RN; Bushman W
J Urol; 1995 Jan; 153(1):233-7. PubMed ID: 7526005
[TBL] [Abstract][Full Text] [Related]
32. ERG expression in intraductal carcinoma of the prostate: comparison with adjacent invasive prostatic adenocarcinoma.
Schneider TM; Osunkoya AO
Mod Pathol; 2014 Aug; 27(8):1174-8. PubMed ID: 24406865
[TBL] [Abstract][Full Text] [Related]
33. Immunoreactivity of ubiquitin in human prostate gland.
Bataineh ZM; Habbal O
Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
[TBL] [Abstract][Full Text] [Related]
34. Disturbed homeostasis of zinc and other essential elements in the prostate gland dependent on the character of pathological lesions.
Sapota A; Darago A; Taczalski J; Kilanowicz A
Biometals; 2009 Dec; 22(6):1041-9. PubMed ID: 19629715
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas.
Fudge K; Wang CY; Stearns ME
Mod Pathol; 1994 Jun; 7(5):549-54. PubMed ID: 7524068
[TBL] [Abstract][Full Text] [Related]
36. CD40 is not detected on human prostate cancer cells by immunohistologic techniques.
Moghaddami M; Cohen P; Stapleton AM; Brown MP
Urology; 2001 Mar; 57(3):573-8. PubMed ID: 11248650
[TBL] [Abstract][Full Text] [Related]
37. BAG-1 expression in hyperplastic and neoplastic prostate tissue: is there any relationship with BCL-related proteins and androgen receptor status?
Bozdogan O; Atasoy P; Bozdogan N; Erekul S; Batislam E; Yilmaz E; Başar MM
Tumori; 2005; 91(6):539-45. PubMed ID: 16457154
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
[TBL] [Abstract][Full Text] [Related]
39. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
40. Alteration of the cytoplasmic/nuclear expression pattern of galectin-3 correlates with prostate carcinoma progression.
van den Brûle FA; Waltregny D; Liu FT; Castronovo V
Int J Cancer; 2000 Jul; 89(4):361-7. PubMed ID: 10956411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
